Healthcare

Despite a challenging start to the year for the healthcare sector, UAE investors are increasingly focusing on the high-growth potential of the GLP-1 drug market, projected to reach $39.4 billion in 2026.

The broader healthcare sector has declined 5.5% year-to-date, underperforming the S&P 500, which is down 3.3%. However, performance within the sector has diverged significantly, highlighting a growing gap between leading and lagging companies.

Pharma Giants Outperform Amid Market Volatility

Several major pharmaceutical companies have delivered strong gains, including Moderna (+65%), Johnson & Johnson (+16.8%), Merck (+14.4%), Pfizer (+12.4%), and Gilead Sciences (nearly +16%).

According to Josh Gilbert of eToro, investors are increasingly favouring companies with strong pipelines, stable earnings, and clear growth catalysts. “Healthcare is becoming a stock-picker’s market,” he noted, emphasising the importance of selectivity amid macroeconomic uncertainty.

GLP-1 Market Presents Long-Term Opportunity

The GLP-1 obesity drug segment remains a major growth driver, with global sales expected to exceed $100 billion by the end of the decade. However, short-term challenges are emerging for key players.

Shares of Novo Nordisk have fallen 24% year-to-date following weaker sales guidance and disappointing trial results for its next-generation obesity drug, CagriSema. Similarly, Eli Lilly has declined 14% amid valuation concerns and uncertainty around market size.

A recent agreement with US authorities to reduce GLP-1 drug prices by 25–35% is also expected to impact revenues, potentially cutting combined US obesity drug sales by $2–3 billion this year.

Emerging Players and Digital Health Trends

New entrants are reshaping the competitive landscape. Hims & Hers Health has gained attention through its partnership with Novo Nordisk, enabling direct-to-consumer access to GLP-1 treatments via digital platforms. The company has built a subscriber base of 2.5 million, reflecting rising demand for accessible, tech-driven healthcare solutions.

Beyond pharmaceuticals, momentum is building in digital health and wearable technology. WHOOP recently secured $575 million in funding at a $10.1 billion valuation, with backing from investors including Mubadala, Qatar Investment Authority, Abbott, and Mayo Clinic. The company has indicated that a potential IPO could follow.

Sector Outlook Remains Strong

Despite near-term pressures, the healthcare sector continues to present a compelling investment case. Its defensive nature remains attractive in volatile markets, while long-term structural trends—including GLP-1 innovation and digital health adoption—are expected to drive sustained growth.

As investors navigate a complex landscape, the shift towards selective investing and emerging healthcare technologies is set to define the sector’s trajectory in the coming years.

• Tags
• #Business
• #Magazine
• #Lifestyle